SCHEMBL1503786

SCHEMBL1503786

O=C(O)Nc1ccncc1S

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 8/20 0.41
KDM4D Q6B0I6 3/20 0.39
MDM4 O15151 1/20 0.38
TP53 P04637 1/20 0.38
NPC1 O15118 1/20 0.37
PKM P14618 1/20 0.37
RAB9A P51151 1/20 0.37
KDM6B O15054 4/20 0.36
MDM2 Q00987 1/20 0.36
TDP1 Q9NUW8 2/20 0.36
TAAR1 Q96RJ0 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
KDM4A O75164 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
SIRT3 Q9NTG7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21214214 0.83 CHUK (0.43) KDM4CTP53NPC1RAB9AMEN1
SCHEMBL27619958 0.81 KDM4C (0.39) KDM4CKDM4DKDM6BTDP1KDM4E
SCHEMBL1043517 0.78 KDM4C (0.46) KDM4CKDM4DNPC1PKMRAB9A
SCHEMBL15017796 0.77 RAB9A (0.45) KDM4CRAB9AROCK2
SCHEMBL6774875 0.77 KDM4C (0.42) KDM4CKDM4DNPC1PKMRAB9A
SCHEMBL4831443 0.77 BCHE (0.46) KDM4CKDM4DNPC1PKMRAB9A
SCHEMBL28824138 0.77 KDM4E (0.53) KDM4CKDM4DKDM6BTDP1KDM4E
SCHEMBL26921540 0.77 GALR3 (0.54) RAB9AKDM4EMEN1MAPTKMT2A
SCHEMBL741240 0.75 NAMPT (0.47) RAB9ANAMPT
SCHEMBL2033252 0.74 KDM4C (0.50) KDM4CKDM4DKDM6BTDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1405852-B9 DIAMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2013-03-27 EP disclosed
EP-1405852-B1 DIAMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2012-08-01 EP disclosed
EP-1415992-B1 DIAMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2012-05-02 EP disclosed
US-20110312990-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-12-22 US disclosed
EP-2343290-A1 Diamine derivatives as factor X inhibitors Daiichi Sankyo Company, Limited (JP) 2011-07-13 EP disclosed
US-20110077266-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-03-31 US disclosed
CN-1751025-B Diamine derivatives DAIICHI SEIYAKU CO 2010-05-12 CN disclosed
US-20100093785-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2010-04-15 US disclosed
US-20090270446-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-10-29 US disclosed
US-7365205-B2 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X DAIICHI SANKYO COMPANY, LIMITED (JP) 2008-04-29 US disclosed
US-7342014-B2 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-11 US disclosed
US-20080015215-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-01-17 US disclosed
US-20050245565-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-03 US disclosed
US-20050119486-A1 Diamine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2005-06-02 US disclosed
US-20050020645-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-01-27 US disclosed
EP-1415992-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 EP disclosed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270446-A1 DIAMINE DERIVATIVES F2, TFPI, F3 KDM4C 2156/4885KDM4D 1203/4885MDM4 4668/4885
US-20050020645-A1 Diamine derivatives C9, C1S, C1R KDM4C 4656/4885KDM4D 4121/4885MDM4 2544/4885
US-20080015215-A1 DIAMINE DERIVATIVES C9, C1S, C1R KDM4C 4656/4885KDM4D 4121/4885MDM4 2544/4885
US-20050245565-A1 Diamine derivatives C9, C1S, C1R KDM4C 4656/4885KDM4D 4121/4885MDM4 2544/4885
US-20100093785-A1 DIAMINE DERIVATIVES C9, C1S, C1R KDM4C 4546/4885KDM4D 3925/4885MDM4 2659/4885
US-20050119486-A1 Diamine derivatives C9, C1S, C1R KDM4C 4656/4885KDM4D 4121/4885MDM4 2544/4885
US-20110077266-A1 Diamine Derivatives F2, TFPI, F3 KDM4C 2156/4885KDM4D 1203/4885MDM4 4668/4885
US-20110312990-A1 Diamine Derivatives C9, C1S, C1R KDM4C 4576/4885KDM4D 4028/4885MDM4 2730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.